Sarepta's fundamentals are characterized by extreme quarterly volatility, with revenue swinging from $744.9M in 2025Q1 to $401.3M in 2026Q2 and gross margins collapsing to 10.0% in 2025Q4, yet the company has deleveraged from a D/E of 1.44 in 2024Q1 to 0.68 in...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.05-123.0% vs $0.22 | $401M+9.5% vs $366M |
Q2 2026 May 6, 2026 | $3.16+223.8% vs $0.98 | $731M+54.1% vs $474M |
Q1 2026 Feb 25, 2026 | -$3.58-247.6% vs -$1.03 | $443M+19.8% vs $370M |
Q4 2025 Nov 3, 2025 | -$1.80-147.6% vs -$0.73 | $399M+18.9% vs $336M |
Squarepoint Ops LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,026 shares of the biotechnology company's stock after selling 48,276 shares during the
Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat.
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
Benchmark SRPT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Sarepta Therapeutics, Inc. (SRPT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.95 | $2B | -2.66 | 15.58% | -32.45% | -53.47% | — | |
| $62.21 | $12.02B | 34.56 | 12.87% | 2.14% | 1.18% | — | |
| $246.51 | $32.91B | 105.80 | 65.19% | 16.82% | 93.61% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $43.93 | $7.3B | -18.46 | 33.87% | -64.64% | -110.84% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Sarepta Therapeutics, Inc. (SRPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Sarepta Therapeutics, Inc. (SRPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 27, 2026·SEC
Jun 4, 2026·SEC
Get notified when SRPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sarepta Therapeutics, Inc. (SRPT) stock FAQ — growth, dividends, profitability & financials explained
Sarepta Therapeutics, Inc. (SRPT) reported $1.97B in revenue for fiscal year 2025. This represents a 1974244% increase from $0.1M in 1996.
Sarepta Therapeutics, Inc. (SRPT) grew revenue by 15.6% over the past year. This is strong growth.
Sarepta Therapeutics, Inc. (SRPT) reported a net loss of $136.7M for fiscal year 2025.
Sarepta Therapeutics, Inc. (SRPT) has a return on equity (ROE) of -53.5%. Negative ROE indicates the company is unprofitable.
Sarepta Therapeutics, Inc. (SRPT) had negative free cash flow of $131.5M in fiscal year 2025, likely due to heavy capital investments.
